

[Help](#) [Logout](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)

Your wildcard search against 2000 terms has yielded the results below

[Search for additional matches among the next 2000 terms](#)**Search Results - Record(s) 1 through 4 of 4 returned.****1. Document ID: US 5889169 A**

Entry 1 of 4

File: USPT

Mar 30, 1999

US-PAT-NO: 5889169

DOCUMENT-IDENTIFIER: US 5889169 A

TITLE: Cell cycle regulatory protein p16 gene

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Demetrick; Douglas J.	E. Northport	NY	N/A	N/A
Serrano; Manuel	Mill Neck	NY	N/A	N/A
Hannon; Gregory J.	Huntington	NY	N/A	N/A
Quelle; Dawn E.	Cordova	TN	N/A	N/A
Sherr; Charles J.	Memphis	TN	N/A	N/A

US-CL-CURRENT: 536/23.5; 530/358, 536/23.7, 536/23.74

ABSTRACT:

The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, these family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa (hereinafter "p16.sup.INK4" OR "p16") and which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth, and that similar to role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16, is in the regulation of the cell-cycle.

29 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Claims](#) [KMC](#) [Image](#)**2. Document ID: US 5876965 A**

Entry 2 of 4

File: USPT

Mar 2, 1999

US-PAT-NO: 5876965
DOCUMENT-IDENTIFIER: US 5876965 A

TITLE: Nucleic acid encoding ARF-19, a novel regulator of the mammalian cell cycle

DATE-ISSUED: March 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sherr; Charles J.	Memphis	TN	N/A	N/A
Quelle; Dawn E.	Cordova	TN	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 530/350, 536/23.1

ABSTRACT:

The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinase from phosphorylating the retinoblastoma protein (pRb), preventing exit from the G1 phase of the cell cycle. Deletions and mutations involving the gene encoding InK4a-p16, INK4A, occur frequently in cancer cells, implying that INK4a-p16, like pRb, suppresses tumor formulation. However, a completely unrelated protein (ARF-p19) arises in major part from an alternative reading frame of the mouse INK4A gene. Expression of an ARF-p19 cDNA (SEQ ID NO:1) in rodent fibroblasts induces both G1 and G2 phase arrest.

13 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

3. Document ID: US 5723313 A

Entry 3 of 4

File: USPT

Mar 3, 1998

US-PAT-NO: 5723313

DOCUMENT-IDENTIFIER: US 5723313 A

TITLE: ARF-p19, a novel regulator of the mammalian cell cycle

DATE-ISSUED: March 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sherr; Charles J.	Memphis	TN	N/A	N/A
Quelle; Dawn E.	Cordova	TN	N/A	N/A

US-CL-CURRENT: 435/69.1; 530/350

ABSTRACT:

The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinase from phosphorylating the retinoblastoma protein (pRb), preventing exit from the G1 phase of the cell cycle. Deletions and mutations involving the gene encoding InK4a-p16, INK4A, occur frequently in cancer cells, implying that INK4a-p16, like pRb, suppresses tumor formulation. However, a completely unrelated protein (ARF-p19) arises in major part from an alternative reading frame of the mouse INK4A gene. Expression of an ARF-p19 cDNA (SEQ ID NO:1) in rodent fibroblasts induces both G1 and G2 phase arrest.

4 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

4. Document ID: WO 9528483 A1, AU 9523845 A, EP 755445 A1, JP 09512424 W, KR 97702366 A, AU 703908 B

Entry 4 of 4

File: DWPI

Oct 26, 1995

DERWENT-ACC-NO: 1995-373798

DERWENT-WEEK: 199933

COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: New cell cycle regulating proteins bind to cyclin dependent kinase - and related nucleic acids, antibodies etc., used in diagnosis and therapy of abnormal cell proliferation, degeneration etc.

INVENTOR: BEACH, D H; DEMETRICK, D J ; HANNON, G J ; SERRANO, M

PRIORITY-DATA:

1994US-0346147	November 29, 1994
1994US-0227371	April 14, 1994
1994US-0248812	May 25, 1994
1994US-0306511	September 14, 1994

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9528483 A1	October 26, 1995	E	109	C12N015/12
AU 9523845 A	November 10, 1995	N/A	000	N/A
EP 755445 A1	January 29, 1997	E	000	N/A
JP 09512424 W	December 16, 1997	N/A	158	C12N015/09
KR 97702366 A	May 13, 1997	N/A	000	C12N015/12
AU 703908 B	April 1, 1999	N/A	000	C12N015/12

INT-CL (IPC): A61 K 38/00; A61 K 38/45; C07 H 21/04; C07 K 14/47; C07 K 16/18; C12 N 15/09; C12 N 15/11; C12 N 15/12; C12 Q 1/68; G01 N 33/53

ABSTRACTED-PUB-NO: WO 9528483A

BASIC-ABSTRACT:

A novel isolated or recombinant cell-cycle regulating (CCR) polypeptide (I), has an amino acid sequence which binds a cyclin-dependent kinase (CDK) and includes ankyrin-like repeats, but is not the human p16 protein (Ia), the 156 residue amino acid sequence of which is given in the specification.

USE - CCR proteins may act as agonists or antagonists of cell-cycle regulation. In partic. they inhibit proliferation/growth of cells (esp. resulting from oncogenic expression of cyclin D1) so may suppress tumour growth, but many other therapeutic applications are contemplated, e.g. in cases of atherosclerosis and restenosis, conditions involving fibrosis, neurodegenerative disease and arrhythmia associated with nerve degeneration etc. Agonists may also be used to maintain cultured neuronal cells at various stages of differentiation, or used in vitro, e.g. to generate prosthetic cartilage devices. Antagonists may be used to immortalise or transform cells. CCR may be admin. as such or generated by gene therapy methods, antisense oligonucleotides may also be used. The primers and probes can be used to determine the level of CCR-encoding nucleic acid in a sample. The CCR proteins are used to: (i) screen cpds. for inhibition of CCR-CDK interaction; and (ii) to identify cpds. that disrupt the ability of CCR to regulate eukaryotic cell cycling. They can also be used to raise diagnostic antibodies. Detection of either a mutation in a CCR gene, or misexpression of the gene is used to identify subjects at risk of developing a cell proliferation disorder, while detecting a CDR-polypeptide complex indicates a risk of cellular transformation.

Term	Documents
CCR	1343
CCRS	53
CELL	596251
CELLS	391975
CYCLE	571615
CYCLES	206216
REGULATORY	22232
REGULATORIES	2
REGULATORYS	0
CDK	220
((CCR OR CELL CYCLE REGULATORY) SAME (CDK OR CYCLIN DEPENDENT KINASE) SAME (ANTIBOD\$ OR MONOCLON\$ OR CCR BINDING PROTEIN)).ALL.	4

[There are more results than shown above, click here to view the entire set.](#)

[Display 25 Documents](#)

including document number

4

[Display Format:](#)

[REV](#)

[Change Format](#)

[Main Menu](#)

[Search Form](#)

[Posting Counts](#)

[Show S Numbers](#)

[Edit S Numbers](#)

[Help](#)

[Logout](#)

[Help](#) [Logout](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#)**Search Results - Record(s) 1 through 25 of 27 returned.****1. Document ID: US 5924077 A**

Entry 1 of 27

File: USPT

Jul 13, 1999

US-PAT-NO: 5924077

DOCUMENT-IDENTIFIER: US 5924077 A

TITLE: Computer based system for monitoring and processing data collected at the point of sale of goods and services

DATE-ISSUED: July 13, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David	Boise	ID	N/A	N/A
Braden; Donald	Layton	UT	N/A	N/A
George; Paul L.	Westboro	MA	N/A	N/A
Meredith; Michael	Kuna	ID	N/A	N/A

US-CL-CURRENT: 705/10; 705/21, 705/7, 707/101

ABSTRACT:

An electronic storage and computing system wherein raw point of sale data is transformed into a predefined standardized configuration from which object values representing select business activities are derived and compared to predefined reference values for the selected activities. The system includes an electronic storage device for storing raw point of sale data, a data interpreter for transforming the raw data into a predefined standardized configuration, and a processor for deriving object values from the transformed data according to a set of mathematical/relational functions, the object values being representative of selected business activities, and comparing the object values to predefined reference values for the selected business activities. The data interpreter operates according to a set of control programs to selectively transfer point of sale data from a set of raw databases into a set of standard databases having a predefined standardized configuration. The mathematical/relational functions are stored in a business rule execution database wherein each function defines an object value for each business activity. A business rule execution engine, which is operatively linked to the processor and the business rule execution database, allows the processor to compute the object values for each business activity according to the corresponding mathematical/relational function, compare the object values and the corresponding reference values, and identify a pass condition representative of an acceptable comparison, a fail condition representative of an unacceptable comparison, or a warn condition representative of a questionable comparison. The identified condition is outputted from the processor and displayed to the user.

41 Claims, 25 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 22

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Claims](#) [KWM](#) [Image](#)**2. Document ID: US 5919997 A**

Entry 2 of 27

File: USPT

Jul 6, 1999

US-PAT-NO: 5919997

DOCUMENT-IDENTIFIER: US 5919997 A

TITLE: Transgenic mice having modified cell-cycle regulation

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Serrano; Manuel	Mill Neck	NY	N/A	N/A
DePinho; Ronald A.	Pelham Manor	NY	N/A	N/A

US-CL-CURRENT: 800/18; 424/9.2, 435/320.1, 435/325, 435/455, 435/463, 435/467, 435/91.2,
800/22, 800/25, 800/3

ABSTRACT:

The present invention relates to transgenic mice in which the biological function of at least one cell cycle regulatory proteins of the INK4 family is altered.

11 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

3. Document ID: US 5889169 A

Entry 3 of 27

File: USPT

Mar 30, 1999

US-PAT-NO: 5889169

DOCUMENT-IDENTIFIER: US 5889169 A

TITLE: Cell cycle regulatory protein p16 gene

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Demetrick; Douglas J.	E. Northport	NY	N/A	N/A
Serrano; Manuel	Mill Neck	NY	N/A	N/A
Hannon; Gregory J.	Huntington	NY	N/A	N/A
Quelle; Dawn E.	Cordova	TN	N/A	N/A
Sherr; Charles J.	Memphis	TN	N/A	N/A

US-CL-CURRENT: 536/23.5; 530/358, 536/23.7, 536/23.74

ABSTRACT:

The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, these family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa (hereinafter "p16.sup.INK4" OR "p16") and which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth, and that similar to role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16, is in the regulation of the cell-cycle.

29 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

4. Document ID: US 5869640 A

Entry 4 of 27

File: USPT

Feb 9, 1999

US-PAT-NO: 5869640
DOCUMENT-IDENTIFIER: US 5869640 A

TITLE: Nucleic acids encoding D-type cyclins and hybridization probes

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A

US-CL-CURRENT: 536/23.7; 435/252.3, 435/320.1, 435/363

ABSTRACT:

The present invention relates to a novel class of cyclins, referred to as D-type cyclins, of mammalian origin, particularly human origin, DNA and RNA encoding the novel cyclins, and a method of identifying other D-type and non-D type cyclins. Also disclosed are a method of detecting an increased level of a D-type cyclin and a method of inhibiting cell division by interfering with formation of the protein kinase-D type cyclin complex essential for cell cycle start.

38 Claims, 35 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 29

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KWMC](#) | [Image](#)

5. Document ID: US 5861249 A

Entry 5 of 27

File: USPT

Jan 19, 1999

US-PAT-NO: 5861249

DOCUMENT-IDENTIFIER: US 5861249 A

TITLE: Assays and reagents for identifying modulators of cdc25-mediated mitotic activation

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Galaktionov; Konstantin	Cold Spring Harbor	NY	N/A	N/A

US-CL-CURRENT: 435/6; 435/7.1

ABSTRACT:

The present invention makes available assays and reagents for identifying agents which can be used to modulate at least one proliferation, differentiation and cell death by apoptosis.

10 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KWMC](#) | [Image](#)

6. Document ID: US 5770423 A

Entry 6 of 27

File: USPT

Jun 23, 1998

US-PAT-NO: 5770423

DOCUMENT-IDENTIFIER: US 5770423 A

TITLE: Nucleic acids encoding cdc25 A and cdc25 B proteins and method of making cdc25 A and cdc25 B proteins

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Galaktionov; Konstantin	Cold Spring Harbor	NY	N/A	N/A

US-CL-CURRENT: 435/197; 607/108, 607/114

ABSTRACT:

Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2 are described. As a result of this work, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases or through alteration of the interaction of components of MPF. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle. Such agents or compositions can be inhibitors (such as low molecular weight peptides or compounds, either organic or inorganic) of the catalytic activity of tyrosine specific PTPases (particularly cdc25), blocking agents which interfere with interaction or binding of the tyrosine specific PTPase with cyclin or the cyclin/cdc2 complex, or agents which interfere directly with the catalytic activity of the PTPases. The invention also pertains to an assay for identifying agents which after stimulation of kinase activity of pre-MPF and thus alter activation of MPF and entry into mitosis. Such agents are also the subject of this invention.

36 Claims, 25 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 25

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KWMC](#) | [Image](#)

7. Document ID: US 5756335 A

Entry 7 of 27

File: USPT

May 26, 1998

US-PAT-NO: 5756335

DOCUMENT-IDENTIFIER: US 5756335 A

TITLE: CDC25A and CDC25B proteins, fusion proteins thereof, and antibodies thereto

DATE-ISSUED: May 26, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Galaktionov; Konstantin	Cold Spring Harbor	NY	N/A	N/A

US-CL-CURRENT: 435/197; 435/69.7, 435/78, 530/350, 530/387.1

ABSTRACT:

Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2 are described. As a result of this work, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases or through alteration of the interaction of components of MPF. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle. Such agents or compositions can be inhibitors (such as low molecular weight peptides or compounds, either organic or inorganic) of the catalytic activity of tyrosine specific PTPases (particularly cdc25), blocking agents which interfere with interaction or binding of the tyrosine specific PTPase with cyclin or the cyclin/cdc2 complex, or agents which interfere directly with the catalytic activity of the PTPases. The invention also pertains to an assay for identifying agents which after stimulation of kinase activity of pre-MPF and thus alter activation of MPF and entry into mitosis. Such agents are also the subject of this invention.

12 Claims, 25 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 25

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

8. Document ID: US 5695950 A

Entry 8 of 27

File: USPT

Dec 9, 1997

US-PAT-NO: 5695950

DOCUMENT-IDENTIFIER: US 5695950 A

TITLE: Method of screening for antimitotic compounds using the cdc25 tyrosine phosphatase

DATE-ISSUED: December 9, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Galaktionov; Konstantin	Cold Spring Harbor	NY	N/A	N/A

US-CL-CURRENT: 435/21; 435/193, 435/194, 435/252.3, 435/320.1, 435/69.1, 435/69.3,
435/69.7, 514/44, 536/22.1, 536/23.1, 536/23.2, 536/23.5

ABSTRACT:

A method of identifying compounds or molecules which alter (enhance or inhibit) stimulation of kinase activity of pre-MPF and, thus, alter (enhance or inhibit) activation of MPF and entry into mitosis. The present method thus makes it possible to identify compounds or molecules which can be administered to regulate the cell cycle; such compounds are also the subject of this invention.

19 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

9. Document ID: US 5672508 A

Entry 9 of 27

File: USPT

Sep 30, 1997

US-PAT-NO: 5672508

DOCUMENT-IDENTIFIER: US 5672508 A

TITLE: Inhibitors of cell-cycle progression, and uses related thereto

DATE-ISSUED: September 30, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gyuris; Jeno	Winchester	MA	N/A	N/A
Lamphere; Lou	Boston	MA	N/A	N/A
Beach; David	Huntington Bay	NY	N/A	N/A

US-CL-CURRENT: 435/320.1; 536/23.4, 536/23.5

ABSTRACT:

The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced. More specifically, the inhibitors of the invention are chimeric proteins which include CDK-binding motifs from two or more different proteins. For example, the subject chimeric proteins can be generated from the in-frame fusion of coding sequences from two different CDK inhibitor proteins, such as may be derived from fusion of coding sequences for an INK4 protein and coding sequences for a CIP protein. Chimeric proteins of the present invention have been observed to be more potent inhibitors of cyclin/CDK complexes than were either of the portions of the chimeric protein individually.

37 Claims, 0 Drawing figures

Exemplary Claim Number: 1

10. Document ID: US 5441880 A

Entry 10 of 27

File: USPT

Aug 15, 1995

US-PAT-NO: 5441880

DOCUMENT-IDENTIFIER: US 5441880 A

TITLE: Human cdc25 genes, encoded products and uses thereof

DATE-ISSUED: August 15, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Galaktionov; Konstantin	Cold Spring Harbor	NY	N/A	N/A

US-CL-CURRENT: 435/193, 435/194, 435/320.1, 435/69.1, 435/69.3, 530/350, 530/387.1,
536/22.1, 536/23.1, 536/23.2, 536/23.5

ABSTRACT:

Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2.

As a result of the work described herein, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases, particularly cdc25 phosphatase, and B-type cyclin or through alteration of the interaction of components of MPF, particularly the association of cdc25 with cyclin, cdc2 or the cdc2/cyclin B complex. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle. Such agents or compositions are, for example, inhibitors (such as low molecular weight peptides or compounds, either organic or inorganic) of the catalytic activity of tyrosine specific PTPases (particularly cdc25), blocking agents which interfere with interaction or binding of the tyrosine specific PTPase with cyclin or the cyclin/cdc2 complex, or agents which interfere directly with the catalytic activity of the PTPases.

22 Claims, 28 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

11. Document ID: US 5294538 A

Entry 11 of 27

File: USPT

Mar 15, 1994

US-PAT-NO: 5294538

DOCUMENT-IDENTIFIER: US 5294538 A

TITLE: Method of screening for antimitotic compounds using the CDC25 tyrosine phosphatase

DATE-ISSUED: March 15, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A

US-CL-CURRENT: 435/21, 435/193, 435/194, 435/320.1, 435/69.1, 435/69.3, 435/69.7, 514/44,
536/22.1, 536/23.1, 536/23.2, 536/23.5

ABSTRACT:

A method of identifying compounds or molecules which alter (enhance or inhibit) stimulation of kinase activity of pre-MPF and, thus, alter (enhance or inhibit) activation of MPF and entry into mitosis. The present method thus makes it possible to identify compounds or molecules which can be administered to regulate the cell cycle; such compounds are also the subject of this invention.

4 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

12. Document ID: US 4881818 A

Entry 12 of 27

File: USPT

Nov 21, 1989

US-PAT-NO: 4881818

DOCUMENT-IDENTIFIER: US 4881818 A

TITLE: Differential imaging device

DATE-ISSUED: November 21, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bustamante; Carlos	Albuquerque	NM	N/A	N/A
Husher; Frederick K.	Albuquerque	NM	N/A	N/A
Beach; David	Albuquerque	NM	N/A	N/A

US-CL-CURRENT: 356/367; 356/364

ABSTRACT:

An apparatus for forming a differential image of a specimen is disclosed. The two images whose difference is used to generate the differential image are made by illuminating said specimen with polarized light, each image corresponding to illuminating the specimen with light of a different polarization. The intensity of the differential image at each point is related to the difference in intensities observed when the point in question is illuminated with light having the different polarizations divided by the sum of said observed intensities. The present invention includes a light source for illuminating the image with polarized light having a polarization which oscillates between first and second preselected states of polarization, said oscillations occurring at a predetermined frequency. The intensity of light leaving each of a preselected plurality of points on the specimen is measured as a function of time by a light detecting apparatus which generates an electrical signal which is related to the intensity of light at the preselected point in question. This electrical signal is used as input to a lock-in amplifier referenced to said predetermined frequency. The output of this amplifier is related to the difference in intensity of the two images at the preselected point in question. The present invention measures the output of the lock-in amplifier and the time averaged input signal to the lock-in amplifier at each of the preselected points and displays the ratio of said output to the time averaged input to the lock-in amplifier as a two dimensional image.

1 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

13. Document ID: US 5770423 A

Entry 13 of 27

File: EPAB

Jun 23, 1998

PUB-NO: US005770423A
DOCUMENT-IDENTIFIER: US 5770423 A
TITLE: Nucleic acids encoding cdc25 A and cdc25 B proteins and method of making cdc25 A and cdc25 B proteins
PUBN-DATE: June 23, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
BEACH, DAVID H	US
GALAKTIONOV, KONSTANTIN	US

INT-CL (IPC): C12 P 19/56; C12 N 5/00; C12 N 9/18; C07 H 17/00

ABSTRACT:

Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2 are described. As a result of this work, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases or through alteration of the interaction of components of MPF. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle. Such agents or compositions can be inhibitors (such as low molecular weight peptides or compounds, either organic or inorganic) of the catalytic activity of tyrosine specific PTPases (particularly cdc25), blocking agents which interfere with interaction or binding of the tyrosine specific PTPase with cyclin or the cyclin/cdc2 complex, or agents which interfere directly with the catalytic activity of the PTPases. The invention also pertains to an assay for identifying agents which after stimulation of kinase activity of pre-MPF and thus alter activation of MPF and entry into mitosis. Such agents are also the subject of this invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	-----------------------

14. Document ID: WO 9740379 A2

Entry 14 of 27

File: EPAB

Oct 30, 1997

PUB-NO: WO009740379A2
DOCUMENT-IDENTIFIER: WO 9740379 A2
TITLE: ASSAYS AND REAGENTS FOR IDENTIFYING MODULATORS OF Cdc25-MEDIATED MITOTIC ACTIVATION
PUBN-DATE: October 30, 1997

INVENTOR-INFORMATION:

NAME	COUNTRY
BEACH, DAVID H	N/A

INT-CL (IPC): G01 N 33/50; G01 N 33/53; C12 Q 1/68; C12 N 5/10

ABSTRACT:

The present invention makes available assays and reagents for identifying agents which can be used to modulate at least one proliferation, differentiation and cell death by apoptosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	-----------------------

15. Document ID: WO 9812339 A2

Entry 15 of 27

File: EPAB

Mar 26, 1998

PUB-NO: WO009812339A2
DOCUMENT-IDENTIFIER: WO 9812339 A2
TITLE: VIRAL VECTORS AND THEIR USES
PUBN-DATE: March 26, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
BEACH, DAVID H	US
HANNON, GREGORY J	US
CONKLIN, DOUGLAS S	US
SUN, PEIQUING	US

INT-CL (IPC): C12 N 15/86; C12 N 15/10; C07 K 14/025

EUR-CL (EPC): C07K014/025 ; C12N015/10 , C12N015/86

ABSTRACT:

The present invention relates to methods and compositions for the elucidation of mammalian gene function. Specifically, the present invention relates to methods and compositions for improved mammalian complementation screening, functional inactivation of specific essential or non-essential mammalian genes, and identification of mammalian genes which are modulated in response to specific stimuli. In particular, the compositions of the present invention include, but are not limited to, replication-deficient retroviral vectors, libraries comprising such vectors, retroviral particles produced by such vectors in conjunction with retroviral packaging cell lines, integrated provirus sequences derived from the retroviral particles of the invention and circularized provirus sequences which have been excised from the integrated provirus sequences of the invention. The compositions of the present invention further include novel retroviral packaging cell lines.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Clip Img	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	--------------------------	-----------------------

16. Document ID: US 5756335 A

Entry 16 of 27

File: EPAB

May 26, 1998

PUB-NO: US005756335A
DOCUMENT-IDENTIFIER: US 5756335 A
TITLE: CDC25A and CDC25B proteins, fusion proteins thereof, and antibodies thereto
PUBN-DATE: May 26, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
BEACH, DAVID H	US
GALAKTIONOV, KONSTANTIN	US

INT-CL (IPC): C12 N 9/18; C12 P 21/06; C12 P 19/56; A61 K 35/14

ABSTRACT:

Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2 are described. As a result of this work, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases or through alteration of the interaction of components of MPF. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle. Such agents or compositions can be inhibitors (such as low molecular weight peptides or compounds, either organic or inorganic) of the catalytic activity of tyrosine specific PTPases (particularly cdc25), blocking agents which interfere with interaction or binding of the tyrosine specific PTPase with cyclin or the cyclin/cdc2 complex, or agents which interfere directly with the catalytic activity of the PTPases. The invention also pertains to an assay for identifying agents which after stimulation of kinase activity of pre-MPF and thus alter activation of MPF and entry into mitosis. Such agents are also the subject of this invention.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

17. Document ID: US 5695950 A

Entry 17 of 27

File: EPAB

Dec 9, 1997

PUB-NO: US005695950A

DOCUMENT-IDENTIFIER: US 5695950 A

TITLE: Method of screening for antimitotic compounds using the cdc25 tyrosine phosphatase

PUBN-DATE: December 9, 1997

INVENTOR-INFORMATION:

NAME	COUNTRY
BEACH, DAVID H	US
GALAKTIONOV, KONSTANTIN	US

INT-CL (IPC): C12 Q 1/42; C12 P 21/06; C12 N 1/20; C12 N 15/00

ABSTRACT:

A method of identifying compounds or molecules which alter (enhance or inhibit) stimulation of kinase activity of pre-MPF and, thus, alter (enhance or inhibit) activation of MPF and entry into mitosis. The present method thus makes it possible to identify compounds or molecules which can be administered to regulate the cell cycle; such compounds are also the subject of this invention.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

18. Document ID: WO 9712962 A1

Entry 18 of 27

File: EPAB

Apr 10, 1997

PUB-NO: WO009712962A1
DOCUMENT-IDENTIFIER: WO 9712962 A1
TITLE: UBIQUITIN LIGASES, AND USES RELATED THERETO
PUBN-DATE: April 10, 1997

INVENTOR-INFORMATION:

NAME	COUNTRY
BEACH, DAVID	US
CALIGIURI, MAUREEN	US
NEFSKY, BRADLEY	US

INT-CL (IPC): C12 N 9/00; C12 Q 1/25

ABSTRACT:

The present invention relates to the discovery in eukaryotic cells of ubiquitin ligases. These proteins are referred to herein collectively as "pub" proteins for Protein UBiquitin ligase, and individually as h-pub1, h-pub2, h-pub3 and s-pub1 for the human pub1, pub2 and pub3 and *Schizosaccharomyces pombe* pub1 clones, respectively. Pub1 proteins apparently play a role in the ubiquitination of the mitotic activating tyrosine phosphatase cdc25, and thus they may regulate the progression of proliferation in eukaryotic cells by activating the cyclin dependent kinase complexes. In *S. pombe*, disruption of s-pub1 elevates the level of cdc25 protein in vivo increasing the activity of the tyrosine kinases, weel and mik1, required to arrest the cell-cycle. Loss of weel function in an *S. pombe* cell carrying a disruption in the s-pub1 gene results in a lethal premature entry into mitosis; such lethal phenotype can be rescued by the loss of cdc25 function. A ubiquitin thioester adduct of s-pub1 can be isolated from *S. pombe* and disruption of s-pub1 dramatically reduces ubiquitination of cdc25.

[Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KMC | Image]

19. Document ID: WO 9711176 A2

Entry 19 of 27

File: EPAB

Mar 27, 1997

PUB-NO: WO009711176A2
DOCUMENT-IDENTIFIER: WO 9711176 A2
TITLE: CYCLIN/CDK ASSOCIATED PROTEINS, AND USES RELATED THERETO
PUBN-DATE: March 27, 1997

INVENTOR-INFORMATION:

NAME	COUNTRY
ZHANG, HUI	US
BEACH, DAVID	US

INT-CL (IPC): C12 N 15/12; C12 N 15/62; C12 N 15/63; C12 N 5/10; A01 K 67/027; C12 Q 1/68; C12 Q 1/00; C07 K 14/47; C07 K 16/18

EUR-CL (EPC): C07K014/47

ABSTRACT:

The present invention relates to S-phase kinase associated proteins, p19 and p45, referred to herein as "Skp". As described herein, these proteins are components of the tumor cell-specific cyclin A/CDK2 complex and function to facilitate DNA replication. Interference with p45 function in vivo prevented entry into S-phase in both normal and transformed cells. Binding data indicated that p45 and p19 associate with each other in a binary complex. Moreover, p45 is required for p19 binding to cyclin A/CDK2.

[Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KMC | Image]

20. Document ID: WO 9612820 A1

Entry 20 of 27

File: EPAB

May 2, 1996

PUB-N0: WO009612820A1

DOCUMENT-IDENTIFIER: WO 9612820 A1

TITLE: INTERACTIONS BETWEEN Raf PROTO-ONCOGENES AND CDC25 PHOSPHATASES, AND USES RELATED THERETO

PUBN-DATE: May 2, 1996

INVENTOR-INFORMATION:

NAME COUNTRY

BEACH, DAVID H N/A

GALAKTIONOV, KONSTANTIN N/A

JESSUS, CATHERINE N/A

INT-CL (IPC): C12 Q 1/42

EUR-CL (EPC): C12Q001/42

ABSTRACT:

The present invention derives from the discovery that CDC25 phosphatases and Raf proteins are able to physically interact to form protein-protein complexes, with the Raf protein mediating the activation of CDC25 phosphatases. The present invention provides both cell-free and cellular assays for detecting agents which modulate the ras-dependent activation of CDC25, as for example, by affecting the binding of a CDC25 protein with Raf, or Raf-associated complexes. Also disclosed is a method for transforming/immortalizing cells, particularly primary cell cultures.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KOMC](#) | [Image](#)

21. Document ID: WO 9528483 A1

Entry 21 of 27

File: EPAB

Oct 26, 1995

PUB-N0: WO009528483A1

DOCUMENT-IDENTIFIER: WO 9528483 A1

TITLE: CELL-CYCLE REGULATORY PROTEINS, AND USES RELATED THERETO

PUBN-DATE: October 26, 1995

INVENTOR-INFORMATION:

NAME COUNTRY

BEACH, DAVID H N/A

DEMETRICK, DOUGLAS J N/A

SERRANO, MANUEL N/A

HANNON, GREGORY J N/A

INT-CL (IPC): C12 N 15/12; C12 N 15/11; C07 K 14/47; C07 K 16/18; C12 Q 1/68; G01 N 33/53

EUR-CL (EPC): C07K014/47 ; C12N009/12 , C07K014/47 , C07K016/18 , C12Q001/68 , C12Q001/68

ABSTRACT:

The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KOMC](#) | [Image](#)

22. Document ID: US 5441880 A

Entry 22 of 27

File: EPAB

Aug 15, 1995

PUB-NO: US005441880A

DOCUMENT-IDENTIFIER: US 5441880 A

TITLE: Human cdc25 genes, encoded products and uses thereof

PUBN-DATE: August 15, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
------	---------

BEACH, DAVID H	US
----------------	----

GALAKTIONOV, KONSTANTIN	US
-------------------------	----

INT-CL (IPC): C12 N 9/10; C12 N 15/00; C12 Q 1/68; C07 H 19/00

EUR-CL (EPC): C07K016/40 ; C12N009/16 , C12Q001/42 , C12Q001/68 , G01N033/50

ABSTRACT:

Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2. As a result of the work described herein, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases, particularly cdc25 phosphatase, and B-type cyclin or through alteration of the interaction of components of MPF, particularly the association of cdc25 with cyclin, cdc2 or the cdc2/cyclin B complex. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle. Such agents or compositions are, for example, inhibitors (such as low molecular weight peptides or compounds, either organic or inorganic) of the catalytic activity of tyrosine specific PTPases (particularly cdc25), blocking agents which interfere with interaction or binding of the tyrosine specific PTPase with cyclin or the cyclin/cdc2 complex, or agents which interfere directly with the catalytic activity of the PTPases.

Full		Title		Citation		Front		Review		Classification		Date		Reference		Claims		KWIC		Image
------	--	-------	--	----------	--	-------	--	--------	--	----------------	--	------	--	-----------	--	--------	--	------	--	-------

23. Document ID: WO 9409135 A1

Entry 23 of 27

File: EPAB

Apr 28, 1994

PUB-NO: WO009409135A1

DOCUMENT-IDENTIFIER: WO 9409135 A1

TITLE: CYCLIN COMPLEX REARRANGEMENT AND USES RELATED THERETO

PUBN-DATE: April 28, 1994

INVENTOR-INFORMATION:

NAME	COUNTRY
------	---------

BEACH, DAVID H	N/A
----------------	-----

XIONG, YUE	N/A
------------	-----

INT-CL (IPC): C12N 15/12; C12N 15/54; C12N 9/12; C12Q 1/68; G01N 33/577

EUR-CL (EPC): C07K014/47 ; C12N009/12 , C07K014/47 , C07K016/18 , C12Q001/68 , G01N033/574

ABSTRACT:

A method and diagnostic kit for diagnosing transformation of a cell, involving detection of the subunit components of cyclin complexes, is disclosed. In particular, the method pertains to the interaction of cyclins, PCNA, CDKs, and low molecular weight polypeptides such as p21, p19 and p16. The invention further pertains to inhibitors of cell proliferation.

24. Document ID: US 5294538 A

Entry 24 of 27

File: EPAB

Mar 15, 1994

PUB-NO: US005294538A

DOCUMENT-IDENTIFIER: US 5294538 A

TITLE: Method of screening for antimitotic compounds using the CDC25 tyrosine phosphatase

PUBN-DATE: March 15, 1994

INVENTOR-INFORMATION:

NAME COUNTRY

BEACH, DAVID H US

INT-CL (IPC): C12Q 1/42; C12P 21/06; C07H 19/00; C07H 21/00

EUR-CL (EPC): C07K016/40 ; C12N009/16 , C12Q001/42 , C12Q001/68 , G01N033/50

ABSTRACT:

A method of identifying compounds or molecules which alter (enhance or inhibit) stimulation of kinase activity of pre-MPF and, thus, alter (enhance or inhibit) activation of MPF and entry into mitosis. The present method thus makes it possible to identify compounds or molecules which can be administered to regulate the cell cycle; such compounds are also the subject of this invention.

25. Document ID: WO 9324514 A1

Entry 25 of 27

File: EPAB

Dec 9, 1993

PUB-NO: WO009324514A1

DOCUMENT-IDENTIFIER: WO 9324514 A1

TITLE: D-TYPE CYCLIN AND USES RELATED THERETO

PUBN-DATE: December 9, 1993

INVENTOR-INFORMATION:

NAME COUNTRY

BEACH, DAVID H N/A

INT-CL (IPC): C07H 21/04; C07K 13/00

EUR-CL (EPC): C07K014/47 ; C12N009/12

ABSTRACT:

A novel class of cyclins is disclosed, referred to as D-type cyclins, of mammalian origin, particularly human origin. Also disclosed is: DNA and RNA encoding the novel cyclins; a method of identifying other D-type and non-D type cyclins; a method of detecting an increased level of a D-type cyclin and a method of inhibiting cell division by interfering with formation of the protein kinase-D type cyclin complex essential for cell cycle start.

Term	Documents
BEACH-DAVID-H	21
BEACH-DAVID-HS	0
BEACH-DAVID	6
BEACH-DAVIDS	0
BEACH-DAVID OR BEACH-DAVID-H	27

including document number

Display Format:

[Main Menu](#)

[Search Form](#)

[Posting Counts](#)

[Show S Numbers](#)

[Edit S Numbers](#)

[Help](#) [Logout](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#)**Search Results -**

Term	Documents
HANNON-GREGORY-J	3
HANNON-GREGORY-JES	0
HANNON-GREGORY-J	3

Database: [All Databases \(USPT + EPAB + JPAB + DWPI + TDBD\)](#) ▼

hannon-gregory-j □ ▼

Refine Search:

Search History

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
ALL	hannon-gregory-j	3	<u>L7</u>
ALL	hannon-gregory\$	35	<u>L6</u>
ALL	serrano-manuel\$	3	<u>L5</u>
ALL	demetrick-douglas\$	2	<u>L4</u>
ALL	beach-david-H or beach-david	27	<u>L3</u>
ALL	beach-david\$	176	<u>L2</u>
ALL	(ccr or cell cycle regulatory) same (cdk or cyclin dependent kinase) same (antibod\$ or monoclon\$ or ccr binding protein)	4	<u>L1</u>

Help Logout**Main Menu Search Form Posting Counts Show S Numbers Edit S Numbers****Search Results - Record(s) 1 through 3 of 3 returned.****1. Document ID: US 5919997 A**

Entry 1 of 3

File: USPT

Jul 6, 1999

US-PAT-NO: 5919997

DOCUMENT-IDENTIFIER: US 5919997 A

TITLE: Transgenic mice having modified cell-cycle regulation

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Serrano; Manuel	Mill Neck	NY	N/A	N/A
DePinho; Ronald A.	Pelham Manor	NY	N/A	N/A

US-CL-CURRENT: 800/18; 424/9.2, 435/320.1, 435/325, 435/455, 435/463, 435/467, 435/91.2,
800/22, 800/25, 800/3**ABSTRACT:**

The present invention relates to transgenic mice in which the biological function of at least one cell cycle regulatory proteins of the INK4 family is altered.

11 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

[Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KMC | Image]**2. Document ID: US 5889169 A**

Entry 2 of 3

File: USPT

Mar 30, 1999

US-PAT-NO: 5889169
DOCUMENT-IDENTIFIER: US 5889169 A

TITLE: Cell cycle regulatory protein p16 gene

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Demetrick; Douglas J.	E. Northport	NY	N/A	N/A
Serrano; Manuel	Mill Neck	NY	N/A	N/A
Hannon; Gregory J.	Huntington	NY	N/A	N/A
Quelle; Dawn E.	Cordova	TN	N/A	N/A
Sherr; Charles J.	Memphis	TN	N/A	N/A

US-CL-CURRENT: 536/23.5; 530/358, 536/23.7, 536/23.74

ABSTRACT:

The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, these family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa (hereinafter "p16.sup.INK4" OR "p16") and which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth, and that similar to role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16, is in the regulation of the cell-cycle.

29 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

3. Document ID: WO 9528483 A1

Entry 3 of 3

File: EPAB

Oct 26, 1995

PUB-N0: WO009528483A1
DOCUMENT-IDENTIFIER: WO 9528483 A1
TITLE: CELL-CYCLE REGULATORY PROTEINS, AND USES RELATED THERETO
PUBN-DATE: October 26, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
BEACH, DAVID H	N/A
DEMETRICK, DOUGLAS J	N/A
SERRANO, MANUEL	N/A
HANNON, GREGORY J	N/A

INT-CL (IPC): C12 N 15/12; C12 N 15/11; C07 K 14/47; C07 K 16/18; C12 Q 1/68; G01 N 33/53

EUR-CL (EPC): C07K014/47 ; C12N009/12 , C07K014/47 , C07K016/18 , C12Q001/68 , C12Q001/68

ABSTRACT:

The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

Term	Documents
SERRANO-MANUEL\$	0
SERRANO-MANUEL	3
SERRANO-MANUEL\$	3

[Display 25 Documents](#)

including document number

1

[Display Format:](#)

[Change Format](#)

[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#)

[Help](#)

[Logout](#)

[Help](#) [Logout](#)[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#)**Search Results - Record(s) 1 through 3 of 3 returned.****1. Document ID: US 5889169 A**

Entry 1 of 3

File: USPT

Mar 30, 1999

US-PAT-NO: 5889169

DOCUMENT-IDENTIFIER: US 5889169 A

TITLE: Cell cycle regulatory protein p16 gene

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beach; David H.	Huntington Bay	NY	N/A	N/A
Demetrick; Douglas J.	E. Northport	NY	N/A	N/A
Serrano; Manuel	Mill Neck	NY	N/A	N/A
Hannon; Gregory J.	Huntington	NY	N/A	N/A
Quelle; Dawn E.	Cordova	TN	N/A	N/A
Sherr; Charles J.	Memphis	TN	N/A	N/A

US-CL-CURRENT: 536/23.5, 530/358, 536/23.7, 536/23.74**ABSTRACT:**

The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, these family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa (hereinafter "p16.sup.INK4" OR "p16") and which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth, and that similar to role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16, is in the regulation of the cell-cycle.

29 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMD](#) | [Image](#)**2. Document ID: WO 9812339 A2**

Entry 2 of 3

File: EPAB

Mar 26, 1998

PUB-NO: WO009812339A2
DOCUMENT-IDENTIFIER: WO 9812339 A2
TITLE: VIRAL VECTORS AND THEIR USES
PUBN-DATE: March 26, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
BEACH, DAVID H	US
HANNON, GREGORY J	US
CONKLIN, DOUGLAS S	US
SUN, PEIQUING	US

INT-CL (IPC): C12 N 15/86; C12 N 15/10; C07 K 14/025

EUR-CL (EPC): C07K014/025 ; C12N015/10 , C12N015/86

ABSTRACT:

The present invention relates to methods and compositions for the elucidation of mammalian gene function. Specifically, the present invention relates to methods and compositions for improved mammalian complementation screening, functional inactivation of specific essential or non-essential mammalian genes, and identification of mammalian genes which are modulated in response to specific stimuli. In particular, the compositions of the present invention include, but are not limited to, replication-deficient retroviral vectors, libraries comprising such vectors, retroviral particles produced by such vectors in conjunction with retroviral packaging cell lines, integrated provirus sequences derived from the retroviral particles of the invention and circularized provirus sequences which have been excised from the integrated provirus sequences of the invention. The compositions of the present invention further include novel retroviral packaging cell lines.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Clip Img	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	--------------------------	-----------------------

3. Document ID: WO 9528483 A1

Entry 3 of 3

File: EPAB

Oct 26, 1995

PUB-N0: WO009528483A1
DOCUMENT-IDENTIFIER: WO 9528483 A1
TITLE: CELL-CYCLE REGULATORY PROTEINS, AND USES RELATED THERETO
PUBN-DATE: October 26, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
BEACH, DAVID H	N/A
DEMETRICK, DOUGLAS J	N/A
SERRANO, MANUEL	N/A
HANNON, GREGORY J	N/A

INT-CL (IPC): C12 N 15/12; C12 N 15/11; C07 K 14/47; C07 K 16/18; C12 Q 1/68; G01 N 33/53

EUR-CL (EPC): C07K014/47 ; C12N009/12 , C07K014/47 , C07K016/18 , C12Q001/68 , C12Q001/68

ABSTRACT:

The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Image](#)

Term	Documents
HANNON-GREGORY-J	3
HANNON-GREGORY-JES	0
HANNON-GREGORY-J	3

[Display 25 Documents](#)

including document number

3

[Display Format:](#)

REV

[Change Format](#)

[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#).

[Help](#) | [Logout](#)

[Help](#) [Logout](#)[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#)**Search Results -**

Term	Documents
HANNON-GREGORY-J	3
HANNON-GREGORY-JES	0
HANNON-GREGORY-J	3

Database: [All Databases \(USPT + EPAB + JPAB + DWPI + TDBD\)](#) ▾

hannon-gregory-j

Refine Search:

Search History

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
ALL	hannon-gregory-j	3	L7
ALL	hannon-gregory\$	35	L6
ALL	serrano-manuel\$	3	L5
ALL	demetrick-douglas\$	2	L4
ALL	beach-david-H or beach-david	27	L3
ALL	beach-david\$	176	L2
ALL	(ccr or cell cycle regulatory) same (cdk or cyclin dependent kinase) same (antibod\$ or monoclon\$ or ccr binding protein)	4	L1